According to a clinical research plan updated by the company in early 2024, Lilly will conduct multiple Phase 3 clinical trials for Retatrutide over the next three years, with targeted indications primarily including obesity, chronic kidney disease, and type 2 diabetes
S1) demonstrated that the sizes of the BSA/AuNCs fall within a narrow range of less than 2 nm
At the same time, oxidative stress (increased ROS) and inflammation interact synergistically, leading to lipid peroxidation damage in the pelvic floor muscles and fascia, impairing their elasticity and contractile capacity
Patients often abandon treatment due to unaffordable out-of-pocket expenses
His6- and GST-tagged protein samples were cleaved using TEV protease, followed by repeated purification on an Ni-NTA column
Convenient once-weekly dosing improves adherence compared to daily regimens [1]